US Patent

US11458103 — Delayed release deferiprone tablets and methods of using the same

Formulation · Assigned to Chiesi Farmaceutici SpA · Expires 2038-10-25 · 12y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects delayed release tablets containing deferiprone for oral administration, specifically for twice daily use.

USPTO Abstract

The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Drugs covered by this patent

Patent Metadata

Patent number
US11458103
Jurisdiction
US
Classification
Formulation
Expires
2038-10-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Chiesi Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.